Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
Ewa Surmiak, Katarzyna Magiera‐Mularz, Bogdan Musielak, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11797-11797
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Peptides as multifunctional players in cancer therapy
Sri Murugan Poongkavithai Vadevoo, Smriti Gurung, Hyun‐Su Lee, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 6, pp. 1099-1109
Open Access | Times Cited: 75
PD-1/PD-L1 and DNA Damage Response in Cancer
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska‐Kołat, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 530-530
Open Access | Times Cited: 22
Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1
Fabian Krutzek, Cornelius K. Donat, Martin Ullrich, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2638-2638
Open Access | Times Cited: 19
Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition
Patrícia Sobral, T. Carvalho, Shiva Izadi, et al.
RSC Advances (2025) Vol. 15, Iss. 4, pp. 2298-2316
Open Access
Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy
Apoorva Mehta, Mateen Motavaf, Ikenna David Nebo, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1200-1200
Open Access
Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
Fabian Krutzek, Klaus Kopka, Sven Stadlbauer
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 747-747
Open Access | Times Cited: 24
Strategies for developing PD-1 inhibitors and future directions
Wensheng Chen, Yuan Huang, Wenting Pan, et al.
Biochemical Pharmacology (2022) Vol. 202, pp. 115113-115113
Open Access | Times Cited: 22
Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold
Lu Lu, Zhihao Qi, Tianyu Wang, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 4, pp. 586-592
Open Access | Times Cited: 18
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Clemens Zwergel, Rossella Fioravanti, Antonello Mai
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103435-103435
Closed Access | Times Cited: 14
Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors
Marta A. Ważyńska, Roberto Butera, Marta Requesens, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9577-9591
Open Access | Times Cited: 8
N-methylmorpholine incorporation into the structure of biphenyl leads to the bioactive inhibitor of PD-1/PD-L1 interaction
Julia Ząber, Łukasz Skalniak, Ganna P. Gudz, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 110, pp. 129882-129882
Open Access | Times Cited: 2
Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1
Fabian Krutzek, Cornelius K. Donat, Martin Ullrich, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15894-15915
Open Access | Times Cited: 6
Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction
Qiaohong Geng, Yanyan Dong, Jin Peng, et al.
Journal of Molecular Structure (2023) Vol. 1289, pp. 135900-135900
Closed Access | Times Cited: 5
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m-Terphenyl Derivatives
Ewa Surmiak, Julia Ząber, Jacek Plewka, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 15, Iss. 1, pp. 36-44
Open Access | Times Cited: 5
Comprehensive Advanced Physicochemical Characterization and In Vitro Human Cell Culture Assessment of BMS-202: A Novel Inhibitor of Programmed Cell Death Ligand
Hasham S. Sofi, Andrea J. Lora, Haley M. Donow, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1409-1409
Open Access | Times Cited: 1
A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition
Xavier Thuru, Romain Magnez, Gérard Vergoten, et al.
Biomedicine Hub (2023) Vol. 8, Iss. 1, pp. 1-9
Open Access | Times Cited: 4
Theoretical and experimental studies on the interaction of biphenyl ligands with human and murine PD-L1: Up-to-date clues for drug design
Greta Donati, Vincenzo Maria D’Amore, Pasquale Russomanno, et al.
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 3355-3368
Open Access | Times Cited: 4
Synthesis and evaluation of indole-containing derivatives as C-linked PD-L1 inhibitors for cancer immunotherapy
Qiaohong Geng, Yanyan Dong, Peng Jin, et al.
Journal of Molecular Structure (2023) Vol. 1294, pp. 136487-136487
Closed Access | Times Cited: 4
Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor
Tess Puopolo, Huifang Li, Justin Gutkowski, et al.
BIO-PROTOCOL (2023) Vol. 13, Iss. 15
Open Access | Times Cited: 3
Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1
Marawan Ahmed, Aravindhan Ganesan, Khaled Barakat
BMC Chemistry (2022) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Nonsymmetrically Substituted 1,1′-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction
Aleksandra Hec, Urszula Tyrcha, Jan Barczyński, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 828-836
Open Access
Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction
Deanne Hayward, Zoë Goddard, Marco M. D. Cominetti, et al.
Chemical Communications (2024) Vol. 60, Iss. 63, pp. 8228-8231
Open Access
Advancing DNAzyme Technology in Tumor Treatment
Jianping Peng, Nini Wang, Rong Xu, et al.
Catalysts (2024) Vol. 14, Iss. 11, pp. 795-795
Open Access
Into the Future: Fighting Melanoma with Immunity
Domenico Corica, Scott D. Bell, P. Miller, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4002-4002
Open Access
In VivoAntitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models
Tadashi Ashizawa, Akira Iizuka, AKARI KANEMATSU, et al.
In Vivo (2024) Vol. 39, Iss. 1, pp. 80-95
Open Access
Page 1 - Next Page

Scroll to top